Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mayne Completes Divestment Of US Generics To Dr Reddy’s

Indian Industry Giant Takes Control Of Australian Firm’s Generics Business

Executive Summary

Mayne Pharma and Dr Reddy’s have announced the completion of a deal that will see the Indian company take over the Australian firm’s US generics business.

You may also be interested in...



Gloomy First Half Results For Mayne

Revenue falls 33% over the half year for the ailing Australian pharmaceutical as it pivots from generics to the branded market

Mayne And Mithra Add Further US NuvaRing Rival

Mayne Pharma and partner Mithra have announced the launch of their Haloette generic version of NuvaRing in the US, adding further competition to a field that already includes Amneal and Teva as well as Prasco’s authorized generic.

Mayne Agrees Deal For TherapeuticsMD’s US Women’s Health Portfolio

Mayne Pharma enters an exclusive US license agreement with TherapeuticsMD for the latter’s women’s health portfolio. Whether the deal will boost their precarious finances is an open question.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel